自閉症障害と治療市場

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, epidemiological surveillance systems, and authoritative health and education organizations. Key sources included the US Food & Drug Administration (FDA) Orange Book and Pediatric Advisory Committee records, European Medicines Agency (EMA) Pediatric Committee (PDCO) decisions, National Institute of Mental Health (NIMH) Research Domain Standards, Centers for Disease Control and Prevention (CDC) Autism and Developmental Disabilities Monitoring (ADDM) Network, National Center for Health Statistics (NCHS) National Survey of Children's Health (NSCH), World Health Organization (WHO) Mental Health and Substance Use Division, National Institutes of Health (NIH) PubMed Central and ClinicalTrials.gov registry, Cochrane Database of Systematic Reviews on Autism Spectrum Disorders, Individuals with Disabilities Education Act (IDEA) Data Center, National Center for Education Statistics (NCES), Autism Speaks Autism Treatment Network (ATN) registry, Autism Society of America National Contact Center data, Autistica (UK) Research Strategy publications, National Autism Association Safety and Treatment Resources, and national health ministry reports from Japan (MHLW), Australia (AIHW), and EU member states via Eurostat Health Database. These sources were utilized to collect epidemiological prevalence statistics, regulatory approval pathways for pediatric indications, clinical safety and efficacy studies on behavioral and pharmacological interventions, diagnostic criteria evolution (DSM-5-TR and ICD-11), treatment cost analyses, and market landscape data for Applied Behavior Analysis (ABA), pharmacotherapies (SSRIs, antipsychotics, anti-convulsants), hyperbaric oxygen therapy, and emerging digital therapeutic platforms.

In order to gather qualitative and quantitative information on treatment acceptance trends, reimbursement dynamics, and pipeline development, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of clinical development, heads of regulatory affairs, commercial directors, and market access leads from pharmaceutical companies (producing SSRIs, antipsychotics, and novel neuromodulatory agents), providers of behavioral health technology platforms (ABA delivery and assessment tools), producers of hyperbaric oxygen therapy devices, and developers of digital therapeutics were examples of supply-side sources. Board-certified developmental-behavioral pediatricians, child and adolescent psychiatrists, Board Certified Behavior Analysts (BCBAs), clinical psychologists, special education directors, medical directors of autism treatment facilities, hospital pharmacy and procurement leads from pediatric hospitals, and payer health plan medical directors in charge of behavioral health policy were among the demand-side sources. Primary research verified therapeutic pipeline timelines for glutamatergic modulators and oxytocin analogs, validated market segmentation across Asperger syndrome, autistic disorder, and pervasive developmental disorder categories, and gathered information on telehealth ABA adoption rates, insurance coverage parity trends, and regulatory pathways for pediatric autism indications.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (30%), Director Level (35%), Others (35%)

• By Region: North America (40%), Europe (25%), Asia-Pacific (20%), Rest of World (15%)

Global market valuation was derived through revenue mapping, procedure volume analysis, and service utilization modeling. The methodology included:

• Identification of 60+ key stakeholders across North America, Europe, Asia-Pacific, and Latin America, encompassing pharmaceutical manufacturers (psychotropic and neurological drug portfolios), behavioral health service providers (ABA therapy chains and platforms), medical device manufacturers (HBOT equipment), and digital health companies (autism-specific diagnostic and therapeutic applications)

• Product mapping across Applied Behavior Analysis (intensive and comprehensive treatment models), pharmacological interventions (SSRIs, atypical antipsychotics, anti-convulsants, stimulants), hyperbaric oxygen therapy protocols, and assistive technology solutions

• Analysis of reported and modeled annual revenues specific to autism disorder treatment portfolios, including direct medical costs (outpatient behavioral therapy, medication management, physician consultations) and indirect cost considerations

• Coverage of manufacturers and service providers representing 75-80% of global market share in 2024

• Extrapolation using bottom-up (therapy hour volumes × reimbursement rates by country; prescription volumes × ASP by drug class; device installations × equipment costs) and top-down (manufacturer revenue validation and pharmaceutical pipeline NPV analysis) approaches to derive segment-specific valuations for behavioral therapies, pharmaceutical treatments, and ancillary therapeutic modalities